Pharmacy Times

AUGUST 8, 2025

2 In patients who had received prior platinum-based chemotherapy but had not been treated with a HER2-targeted TKI or antibody-drug conjugate (ADC; n = 71), the ORR was approximately 75% (95% CI, 63–83), with 58% of patients achieving a DOR of at least 6 months. August 8, 2025. Accessed August 8, 2025. Updated July 28, 2025.

FDA

Pharmacy Times

JUNE 9, 2025

A retrospective study presented at the American Society of Health-System Pharmacists 2025 Pharmacy Futures meeting has revealed significant variability in asthma treatment regimens following initial diagnosis, with many patients not receiving care aligned with the Global Initiative for Asthma (GINA) recommendations. Accessed June 9, 2025.

Compounding Pharmacies

Pharmacy Times

AUGUST 13, 2025

2 Len enhances immune response and promotes antibody-dependent cellular cytotoxicity, whereas R targets CD20-expressing B cells. 4,5 This multimodal immune engagement likely contributes to the response observed even in patients with low CD30 expression.

HIV Treatment and Prevention Agents

Pharmacy Times

JUNE 11, 2025

Image Credit: © Chinnapong - stock.adobe.com At the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025, an encore presentation from the Pacific Coast Reproductive Society Annual Meeting will highlight findings from a retrospective analysis conducted by Walgreens Specialty Pharmacy.

Specialty Pharmacies

Pharmacy Times

JUNE 17, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Proactive strategies in oncology care enhance financial sustainability and improve patient outcomes.

Mail-Order Pharmacies

Pharmacy Times

JUNE 23, 2025

Soefje, PharmD, MBA, BCOP, during the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon. Presented at: Hematology/Oncology Pharmacy Association 2025 Annual Conference; April 9-12, 2025; Portland, OR. That’s the system we are headed into very rapidly.” REFERENCE Soefje SA.

FDA

Pharmacy Times

JUNE 20, 2025

Pharmacy Times : Can you share what you presented at the 2025 OPC meeting? Heidi Finnes, PharmD, BCOP, FHOPA : I shared new hope in cutaneous malignancies and abstracts from the 2025 ASCO meeting. Heidi Finnes, PharmD, BCOP, FHOPA : I shared new hope in cutaneous malignancies and abstracts from the 2025 ASCO meeting.

Compounding Pharmacies

Pharmacy Times

JUNE 13, 2025

Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.

Chemotherapy

Pharmacy Times

AUGUST 14, 2025

Paraneoplastic stiff syndrome is associated with malignancy and tends to progress more quickly, often requiring chemotherapy and/or radiation as well as immunotherapy. The treatment of SPS focuses mainly on symptom management, such as myalgias, and reducing the immune system’s hyperactivity.

HIV Treatment and Prevention Agents

Pharmacy Times

JUNE 12, 2025

Because biologics and biosimilar products are large and complex proteins, there is a higher risk of a patient’s body identifying them as an “outside source” and mounting an immune response to them.

Immunization

Pharmacy Times

JUNE 20, 2025

Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Carlstrom, PharmD, BCOP , Joseph A. Kalis, PharmD, BCOP Key Takeaways Oncology pharmacy's complexity outpaces the generalist model, necessitating specialization for effective patient care and operational efficiency.

Compounding

Pharmacy Times

JULY 9, 2025

SHOW MORE Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy. The authors wrote that their findings could serve as a baseline for the steroids’ negative independent prognostic factor in patients with NSCLC undergoing ICI therapy.

Immunization

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 22, 2025

A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. While the European Medicines Agency mandated pre-treatment DPD testing in Europe as early as 2020, and the UK’s National Health Service followed suit the same year, the US only reached a consensus in 2025.

Compounding Pharmacies

Pharmacy Times

AUGUST 14, 2025

At the 2025 Advanced Topics for Oncology Pharmacy Professionals Summit in Salt Lake City, Utah, these shifting responsibilities were explored in a general session and panel discussion, which included Pharmacy Practice in Focus: Oncology editorial advisory board member Kirollos S.

Documentation

Pharmacy Times

JUNE 9, 2025

At the 2025 American Society of Health-System Pharmacists Pharmacy Futures meeting, Esther E. Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures. Charlotte, NC; June 9, 2025. SHOW MORE Standardized online modules ensure consistent, high-quality care in collaborative practice agreements.

Compounding Pharmacies

Pharmacy Times

JUNE 25, 2025

Pharmacy Times : Can you share what you presented at the 2025 OPC meeting? Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. Kevin Chen, PharmD, MS, BCOP, CPP : Yeah, I presented some therapeutic training updates from ASCO for the treatment of thoracic cancers like lung cancer.

Compounding Pharmacies

Pharmacy Times

JUNE 10, 2025

June 10, 2025. Accessed June 10, 2025. Related Videos Related Content Advertisement June 10th 2025 Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems Aislinn Antrim, Managing Editor June 3rd 2025 S2. PR Newswire. Meloxicam: Selective COX-2 inhibition in clinical practice.

HIV Treatment and Prevention Agents

Pharmacy Times

JUNE 17, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. The abstract was originally shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Dosage

Pharmacy Times

JULY 23, 2025

Pharmacy Times : Can you share what you presented at OPC 2025? So I think the study really showed the benefit of remote clinical monitoring after starting chemotherapy. Eugene Przespolewski, PharmD, BCOP, DPLA : At OPC, I presented a few different topics, really focused on care models and optimization.

Specialty Pharmacies

Pharmacy Times

JUNE 19, 2025

2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. Accessed January 17, 2025. With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. September 12, 2024.

Compounding

Pharmacy Times

AUGUST 13, 2025

Low- and intermediate-risk patients typically receive transurethral resection of bladder tumor with a single dose of perioperative intravesical chemotherapy. And it appears that having the chemotherapy released slowly over weeks rather than in just a few hours is a much more effective approach.”

Compounding Pharmacies

Pharmacy Times

JUNE 27, 2025

I recently had the opportunity to blend my own science and philosophy at the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon, presenting on psychedelic medicines in oncology and palliative care.

Compounding Pharmacies

Pharmacy Times

JUNE 11, 2025

Completion Date (Estimated): December 31, 2025 TRUST-II Trial Name: Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) ClinicalTrials.gov ID: NCT04919811 Sponsor: Nuvation Bio Inc. Additionally, patients may have received prior chemotherapy for advanced disease.

FDA

Pharmacy Times

JUNE 9, 2025

At the 2025 American Society of Health-System Pharmacists (ASHP) Pharmacy Futures meeting, 4 pharmacy leaders from major health systems gathered for a candid panel discussion about the rapidly evolving role of pharmacists in managing advanced therapeutics, including cell and gene therapies. Accessed June 9, 2025.

Compounding Pharmacies

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy

Pharmacy Times

JUNE 18, 2025

Results will be shared at the 2025 Oncology Pharmacists Connect meeting, potentially aiding oncology pharmacists in refining treatment strategies for sAML. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Compounding Pharmacies

Pharmacy Times

JULY 14, 2025

TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy. July 9, 2025. Accessed July 10, 2025.

FDA

Pharmacy Times

JUNE 18, 2025

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy.

Chemotherapy

Pharmacy Times

AUGUST 7, 2025

Methods Patients aged 18 to 59 years with t-AML or AML-MRC treated with CPX-351 or 7+3 as induction chemotherapy between 2015 and 2022 at 3 National Cancer Institute–designated cancer centers were included. Study Design Retrospective, multicenter, observational cohort study.

Chemotherapy

Pharmacy Times

JULY 3, 2025

I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.

Specialty Pharmacies

Pharmaceutical Technology

JULY 1, 2025

July 1, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The therapy can be administered either intravenously or subcutaneously. Credit: HenadziPechan/Shutterstock. By GlobalData Learn more about Strategic Intelligence Gammagard liquid ERC is approved under the brand name Deqsiga by the European Medicines Agency.

FDA

Blog: Ask a Student Pharmacist

JULY 25, 2025

Owatonna eomizowh Fri, 07/25/2025 - 14:31 Owatonna, Minnesota, is a vibrant city located in Steele County, approximately 70 miles south of the Twin Cities. Students will be participating in the pharmacy’s immunization program, the medication therapy management program, and in pharmacy dispensing functions.

Mayo Clinic

Pharmacy Times

JUNE 19, 2025

Visualization of human lungs with cancer | Image Credit: © iDoPixBox - stock.adobe.com At the 2025 American Society of Clinical Oncology Annual Meeting, experts discussed genomic insights in perioperative decision-making in early-stage NSCLC, navigating EGFR and ALK mutations, and the emergence of other biomarkers.

Chemotherapy

Pharmacy Times

AUGUST 12, 2025

Usual treatments like chemotherapy, hormone therapy, radiation, and surgery have undeniably helped patients live longer. SHOW MORE Natural compounds like prunus armeniaca and bee venom enhance breast cancer treatment, boosting efficacy and reducing side effects. Yet, these come with substantial adverse effects and, often, therapy resistance.

Compounding

The Thyroid Pharmacist

AUGUST 1, 2025

Benefits for the Baby Human breast milk is nutrient-rich and contains a variety of anti-inflammatory, immune-protective, and antimicrobial properties that support your baby’s immune system and reduce the risk of lower respiratory tract infections, ear infections (otitis media), and gastroenteritis. What does the research say?

Health and Personal Care Stores

Pharmacy Times

JUNE 25, 2025

Updated June 18, 2025. Accessed June 18, 2025. Jim Ruble, PharmD, JD June 3rd 2025 S2. CNN Health. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies